Four Cases of X-Linked Hypophosphatemic Rickets, Clinical Description and Genetic Testing

David Vila-Pérez1*, Silvia Marín-del-Barrio2, Jordi Vila-Cots1, Jose Antonio Camacho-Díaz1, Marcos Morey3, Lourdes Loidi3

1Department of Nephrology, Hospital Sant Joan de Déu, Barcelona, Spain
2Department of Endocrinology, Hospital Sant Joan de Déu, Barcelona, Spain
3Department of Genomics, Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain

Email: *dvila@hsjdbcn.org

Received 12 January 2014; revised 10 February 2014; accepted 8 March 2014

Abstract

One of the major causes of congenital hypophosphatemic rickets is the X-linked hypophosphatemic rickets (XHR), due to a defect on PHEX gene. The XHR increases the renal elimination of phosphate, that condition leads a defective mineralization of bones and also affects the growth in children. Clinical diagnosis should be suspected in children with signs of rickets and hypophosphatemia with normal calcium levels. We describe clinical characteristics and genetic results of four patients diagnosed and treated in our Nephrology Section. All patients have a “de novo” XHR as none familiars are affected. Early diagnosis should be suspected before the bone deformities have been submitted and the growth would have been impaired.

Keywords

Rickets; X-Linked Hypophosphatemic Rickets; XHR; PHEX Gene

1. Introduction

X-linked hypophosphatemic rickets (XHR, OMIM 307800) is a dominant inherited disorder characterized by renal phosphate wasting, leading to chronic hyperphosphaturia and hypophosphatemia, which are associated to unsuitable normal or low levels of 1.25(OH)2 Vitamin D3. This phosphorus-wasting disturbance affects bone metabolism, yielding rickets in pediatric patients and osteomalacia in adults [1]-[4].

*Corresponding author.

Parathyroid hormone (PTH) and Fibroblast Growth Factor 23 (FGF-23) act as phosphaturic agents, reducing phosphorus reabsorption in the proximal tubules, through NaPiT-II co-transporters inhibition. In XHR, hyperphosphaturia derives from mutations in the PHEX gene (Phosphate regulating gene with homologies to Endopeptidases on the X-chromosome) (1 - 3, 13 - 16). This gene, whose locus is Xp22.1, encodes a membrane endopeptidase, called PHEX, mainly expressed in bone and teeth [1]-[7].

The mutations in PHEX gene associated to XRH yield a decrease or absence of action of PHEX, thus increasing FGF-23 actions in the inactivation of NaPiT-II co-transporters, leading to a decreased phosphorus tubular reabsorption [1]-[7]. In XRH, dentin mineralization is impaired, with the defect appearing as unmerged, persistent mineralization foci surrounded by extensive interglobular regions of unmineralized dentin matrix [8]. These abnormalities may lead to rapid pulp necrosis associated with periapical bone infection.

2. Subjects and Methods

The patients described here were diagnosed with XHR in our center and are visited regularly in the Nephrology and Endocrinology Services. Diagnosis of XHR was based on clinical and radiological findings of rickets, skeletal deformities, and growth impairment as well as laboratory data indicating hypophosphatemia.

We reviewed the medical records from the patients and data of clinical aspects and laboratory testing was collected. In all genetic study has been undertaken after diagnosis and once initiated treatment. We used peripheral blood samples for genetic testing that were refered to a external laboratory, where techniques as real time polymerase chain reaction and multiplex ligation dependent probe amplification assay were performed.

Informed consent was obtained from the patients or their parents. The authors declare no conflict of interest.

3. Results

There were 4 patients followed in our service, half of them males. All of them were referred by their pediatrician to our center with suspect of rickets, mainly by tibia vara and short height. Diagnostic was made between 2 and 4 years of life. All of them presented with clinical and radiological signs of rickets at diagnosis and with hypophosphatemia and normocalcemia. In Table 1, there are summarized some clinical and laboratory findings at diagnosis.

All the patients had grown impairment (with height percentiles between P1 and P19 according to age). During the follow up data growth data was recorded and summarized in Table 2.

The treatment undertaken was phosphate and calcitriol. The phosphate was in form of Solution of Joulie at doses between 60 and 100 mg/kg/day of phosphate. The dose of calcitriol was 0’25 mcg twice a day in all patients.

Three of the patients referred a transient secondary hyperparathyroidism, with levels of parathyrine between 16’8 and 33’3 pmol/L (normal values 0.5 - 5.5 pmol/L).

The genetic tests performed showed different mutations. The patient 1 did not present any punctual mutation of PHEX gene. A multiplex ligation dependent probe amplification assay was performed and it suggested a deletion of exon 3 of PHEX. The patient 2 had the mutation NM_000444.4:c.565C  > T (p.Gln549X) in exon 5 of PHEX that encoded a premature stop codon. In patient 3, there was found the mutation NM_000444.4:c.591A  > G (c.591A > G) in exon 5 of PHEX, that encoded a change of the nucleotide, an adenine instead of a guanine, in the third position of codon number 197. The patient 4 was found to have the mutation NM_000444.4:c.1645C  >

| Table 1. Clinical and genetical description of patients. |
|----------------|----------------|----------------|----------------|
|               | Patient 1       | Patient 2       | Patient 3       | Patient 4       |
| Gender        | Female          | Male            | Male            | Female          |
| Age at diagnosis (months) | 34              | 24              | 41              | 50              |
| Rickets signs | Tibia vara growth retardation | Tibia vara ankle deformation | Tibia vara | Tibia vara |
| Calcium ionic at diagnosis (mmol/L) | 2’42         | 2’48             | 2’35             | 2’54             |
| Phosphate at diagnosis (mmol/L) | 0’84             | 0’99             | 0’95             | 0’80             |
| Alcaline phosphatase at diagnosis (U/L) | 558           | 738              | 449              | 448              |
Table 2. Height characteristics of patients.

<table>
<thead>
<tr>
<th></th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Female</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Age at diagnosis (months)</td>
<td>34</td>
<td>24</td>
<td>41</td>
<td>50</td>
</tr>
<tr>
<td>Height at diagnosis (cm)</td>
<td>86</td>
<td>81</td>
<td>96</td>
<td>96</td>
</tr>
<tr>
<td>Height percentile at diagnosis (SD)</td>
<td>P2 (−2.3)</td>
<td>P &lt; 1 (−2.4)</td>
<td>P19 (−0.9)</td>
<td>P2 (−2.1)</td>
</tr>
<tr>
<td>Age at end of follow up (years)</td>
<td>15</td>
<td>5</td>
<td>8</td>
<td>16</td>
</tr>
<tr>
<td>Height at end of follow up</td>
<td>149</td>
<td>101</td>
<td>114</td>
<td>151</td>
</tr>
<tr>
<td>Height percentile at end of follow up (SD)</td>
<td>P &lt; 1 (−2.4)</td>
<td>P &lt; 1 (−2.35)</td>
<td>P &lt; 1 (−2.6)</td>
<td>P2 (−2.1)</td>
</tr>
</tbody>
</table>

T (p.Arg549X) in exon 15 of PHEX gene that encoded a premature stop codon. There were no familiars affected and none of the mothers had the same mutation as any of the patients.

4. Discussion

Rickets is a disease characterized by defective mineralization of osteoid matrix during growth, leading to the development of bone defects and the presence of short stature. One of the causes of rickets is hypophosphatemia, which is usually presented without the characteristic signs of hypocalcemic rickets such as involvement of ribs and upper limbs. The main causes of hypophosphatemic rickets in the developed world are the familiar rickets, and one of the most frequent is familial X-linked hypophosphatemic rickets (XHR) [9]-[12].

The XHR is characterized by an increased renal elimination of phosphate which leads to a hypophosphatemia with normal calcium levels. The causative mechanism is an alteration in the regulatory mechanisms of major renal phosphate transporter, the transporter NaPiT-II. In the XHR, the FGF-23 levels, whose functions are the inhibition of the transporter NaPiT-II and to inhibit the activity of the 25 (OH)-1-hydroxylase impairment, are increased and leads to a raise in phosphaturia [1] [13]-[16].

This increase in FGF-23 is produced by a deficit of PHEX protein, a transmembrane protein that promotes FGF-23 cleavage in smaller and two inactive peptides, encoded by the gene PHEX, located on chromosome Xp22.1 [1]-[7] [17].

The diagnosis of XHR is based on a consistent medical history and physical examination, radiological evidence of rachitic disease, compatible laboratory values and a family history consistent with XHR or the demonstration of PHEX mutations [18].

In our study, all our patients had predominantly lower limb abnormalities, short stature and compatible laboratory testing, summarized in Table 1, showing a low phosphate with normal calcemia. Alkaline phosphatase is useful at the time of diagnosis to monitor the treatment side.

The genetic testing is usually performed as a confirmatory test in addition to ensure proper genetic counseling. Patients 2 and 4 had two mutations already described in the literature, leading to the presence of a premature stop codon and thus an abnormal protein [19] [20].

In the first patient, we did not detect any mutation in the gene sequencing, which is why a study by MLPA was undertaken, which showed a lack of the exon 3 of PHEX gene. The MLPA technique can detect the presence of deletions in the gene PHEX effectively as they have been shown in some studies [21].

In the case of patient 3, presenting the mutation (c.591A > G) corresponds to exon 5 of the PHEX gene. This mutation causes a change in the nucleotide (an adenine by a guanine) in the third position of codon 197. Theoretically, this change would not cause any amino acid change, however were made theoretical predictions of mRNA by “Splice Site Finder-like”, “Max Ent Scan” and “NNSPLICE” that pointed to the emergence of an abnormal splicing site resulting in a shorter exon and therefore to an abnormal protein. This mutation has recently been described [21].

All our 4 patients sterted a Joulie solution treatment as a method of administration of phosphate with the administration of calcitriol. Secondary, hyperparathyroidism is a frequent complication of this treatment due to direct parathyroid stimulation by inorganic phosphate (Pi); others may develop even a tertiary hyperparathyroidism. That condition increases phosphaturia despite hypophosphatemia. In our case, we lowered the dose of Pi; but
there has been reported the use of calcimimetics with apparently good results [22]-[24].

Despite adequate treatment, the growth at follow-up remained below 2 standard deviations of the normal range for their age. According the published data, the cumulative growth deficit prior to diagnosis is the main cause of a low final height [25]-[27].

Growth hormone increases glomerular filtration rate and effective renal plasma flow, and it has been found to increase the renal phosphate reabsorption in animal models [28], moreover growth hormone treatment stimulates bone remodeling [29]-[31]. For these reasons there have been several studies with recombinant human growth hormone (rhGH) in children suffering from XHR to prevent a final stature at the end of puberty.

According to these studies appears to be an improvement in final height [32] [33] although it may aggravate pre-existing skeletal deformities [34], but the low number of cases and the lack of randomized studies do not allow recommendations.

In conclusion, although the diagnosis is mainly clinical, molecular genetic tests can help make an early diagnosis, before the bone deformities have been submitted and the growth would have been impaired.

Acknowledgements

We would like to thank Dr. L. Loidi and her team from Fundación Pública Galega de Medicina Xenómica for their support in genetic testing.

References


D. Vila-Pérez et al.


X-Linked Hypophosphatemia. *Pediatrics*, **100**, 879-884. [http://dx.doi.org/10.1542/peds.100.5.879](http://dx.doi.org/10.1542/peds.100.5.879)


**Abbreviations**

XHR: X-Linked hypophosphatemic rickets  
PTH: Parathyroid hormone  
FGF-23: Fibroblast Growth Factor 23  
PHEX: Phosphate regulating gene with homologies to endopeptidases on the X-chromosome  
SD: Standard deviation